Novotech has the capability and experience to deliver global projects for Biotechs

Novotech acquires European CRO, EastHORN as part of global expansion program- Read News Release 

Novotech Acquires US-based Drug Development Consulting Firm, CBR International - Expands Drug Development and FDA Regulatory Expertise- Read News Release 

Regions where we operate

Regions where we operate

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Click for more

Europe

  • Europe has a thriving biotech sector and with European based CRO, EastHORN joining Novotech our presence give us improved access to this client base.
  • Europe is an attractive clinical development region due to the commercial size of the end market, and availability of large patient populations (particularly in central and Eastern Europe).
  • Europe has been a leader in the regulation of biosimilars, and so many of these trials occur in Europe.

Click for more

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators

Click for more

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies

Click for more

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees

Click for more

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Click for more

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English

Click for more

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure

Click for more

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018

Click for more

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost

Click for more

United States of America

  • Following the acquisition and integration of a long standing full-service CRO partner, Novotech now provides services across the United States"

Click for more